Fair Value REIT-AG: Geschäftsjahr 2025 im Rahmen der Prognose - Mieteinnahmen und FFO I rückläufig Mieteinnahmen sinken um 0,6 Mio. Euro auf 19,1 Mio. Euro Bereinigtes operatives Ergebnis (FFO I nach Steuern, vor Minderheiten) verringert sich um 1,1 Mio. Euro auf 11,5 Mio. Euro Leerstand von 14,6 % auf 9,8 % verringert Prognose für 2026: Mieteinnahmen von 17,0 Mio. bis zu 18,0 Mio. Euro sowie FFO ...
Fair Value REIT-AG: Geschäftsjahr 2025 im Rahmen der Prognose - Mieteinnahmen und FFO I rückläufig Mieteinnahmen sinken um 0,6 Mio. Euro auf 19,1 Mio. Euro Bereinigtes operatives Ergebnis (FFO I nach Steuern, vor Minderheiten) verringert sich um 1,1 Mio. Euro auf 11,5 Mio. Euro Leerstand von 14,6 % auf 9,8 % verringert Prognose für 2026: Mieteinnahmen von 17,0 Mio. bis zu 18,0 Mio. Euro sowie FFO I zwischen 8,0 Mio. und 9,0 Mio. Euro Langen, den 19. März 2026. Die Fair Value REIT-AG (ISIN: DE000A0MW975) hat im Geschäftsjahr 2025 ihre Jahresprognosen zu den Mieteinnahmen sowie die Ergebniskennzahl Funds from Operations I (FFO I nach Steuern, vor Minderheiten) trotz unsicherer wirtschaftlicher Rahmenbedingungen erreicht. Für 2026 erwartet der Vorstand im Vergleich zu 2025 niedrigere Mieteinnahmen und FFO I. Vermietungserfolge und Veräußerung lassen Leerstandsquote sinken Im vergangenen Jahr lagen die Mieteinnahmen von 19,1 Mio. Euro unterhalb des Vorjahreswertes von 19,7 Mio. Euro, aber dennoch leicht oberhalb der erwarteten Spanne der Mieteinnahmen von 18,0 Mio. bis 19,0 Mio. Euro. Die gesunkenen Mieteinnahmen gehen primär auf Auszüge von insolventen Mietern und den Verkauf des Objektes in Osnabrück im Vorjahr zurück. Gegenläufig wirkten Mieterhöhungen aus indexierten Mietverträgen und neu abgeschlossene Mietverträge wie beispielsweise in Rostock, wo die Mieteinnahmen zugleich um rund 15 % gesteigert wurden. Das um Bewertungs- und Sondereffekte bereinigte Konzernergebnis FFO I erreichte 11,5 Mio. Euro (Vorjahr: 12,6 Mio. Euro). Damit lagen die FFO I am oberen Ende der im März 2025 veröffentlichen Prognose von 10,5 Mio. bis 11,5 Mio. Euro. Die EPRA-Leerstandsquote sank zu Ende 2025 auf 9,8 % (2024: 14,6 %). Der Leerstandsrückgang ist sowohl auf die Veräußerung der leerstehenden Einzelhandelsimmobilie in Querfurt als auch auf Vermietungserfolge, insbesondere in Rostock und Langenfeld, zurückzuführen. Das Ergebnis vor Zinsen und Steuern (EBIT) sank 2025 nach 2,8 Mio. Eu...
夏寶龍會見陳茂波一行 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】財政司司長陳茂波展開北京訪問行程。 港澳辦主任夏寶龍早上會見陳茂波一行人。夏寶龍表示，「十五五」規劃綱要支持香港鞏固和提升競爭優勢，相信特區政府...
夏寶龍會見陳茂波一行 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】財政司司長陳茂波展開北京訪問行程。 港澳辦主任夏寶龍早上會見陳茂波一行人。夏寶龍表示，「十五五」規劃綱要支持香港鞏固和提升競爭優勢，相信特區政府會帶領社會各界結合實際，制定好香港首個五年規劃，為本港的經濟注入更大動能。陳茂波亦向他匯報本港經濟發展形勢和金融情況。陳茂波下午亦分別拜會人民銀行行長潘功勝和中國證監會主席吳清，討論金融市場發展和監管合作事宜。
Retail giants Walmart and Target are deploying artificial intelligence to revolutionize supply chain efficiency and enhance profitability for long-term growth
Retail giants Walmart and Target are deploying artificial intelligence to revolutionize supply chain efficiency and enhance profitability for long-term growth
Key Points J&J has gone through several shifts in recent years -- and demonstrated its strength. The company has many products and platforms that deliver billion-dollar revenue. 10 stocks we like better than Johnson & Johnson › Johnson & Johnson (NYSE: JNJ) reached a transition point a few years ago. The company spun off its consumer health business into Kenvue in order to shift its focus and fina...
Key Points J&J has gone through several shifts in recent years -- and demonstrated its strength. The company has many products and platforms that deliver billion-dollar revenue. 10 stocks we like better than Johnson & Johnson › Johnson & Johnson (NYSE: JNJ) reached a transition point a few years ago. The company spun off its consumer health business into Kenvue in order to shift its focus and financial resources to its innovative medicine and medtech businesses. J&J did this because these areas showed stronger growth potential moving forward. Meanwhile, J&J's top-selling drug, immunology drug Stelara, lost exclusivity, representing a clear headwind for the pharma giant. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Since those times, J&J has demonstrated its strength: It's successfully managed the growth of its two main businesses -- even through declines of Stelara. Now, here are two reasons to buy J&J like there's no tomorrow. 1. Strength during times of uncertainty The S&P 500 has slipped this year, amid a variety of concerns, from questions about spending on artificial intelligence (AI) to worries about the war in Iran. Meanwhile, J&J shares have climbed 15%. Pharma stocks generally perform well during times of uncertainty because investors know that risks to their growth are limited -- patients need their medicines and procedures regardless of the economic backdrop. All of this means pharma players are great stocks to own during such environments. And the reason why J&J in particular makes a solid buy now is that the company's portfolio is looking strong. J&J has 28 platforms or products bringing in at least $1 billion annually. In fact, the company recently said it can now place the Stelara loss of exclusivity "in the rearview mirror." 2. Dividend growth J&J is a Dividend King, meaning it'...
Miguel Fernandez Castro/iStock via Getty Images Elliott Investment Management has built a significant stake in Align Technology ( ALGN ), the maker of Invisalign teeth-straightening products, according to a report by Bloomberg News. The activist fund is planning to engage with Align to encourage it to explore ways to lift the company’s stock price, the report said. Elliott’s stake in Align ( ALGN ...
Miguel Fernandez Castro/iStock via Getty Images Elliott Investment Management has built a significant stake in Align Technology ( ALGN ), the maker of Invisalign teeth-straightening products, according to a report by Bloomberg News. The activist fund is planning to engage with Align to encourage it to explore ways to lift the company’s stock price, the report said. Elliott’s stake in Align ( ALGN ) makes it one of the dental device company’s largest investors, the people said. The company's shares have gained 10.4% YTD. More on Align Technology Align Technology, Inc. (ALGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Align Technology, Inc. (ALGN) Presents at Leerink Global Healthcare Conference 2026 Transcript Align Technology: Broad-Based Q4 Outperformance Supports Upside Align Tech upgraded at Barclays on valuation Align Technology outlines 3%–4% revenue growth target for 2026 as DSO momentum and digital innovation drive outlook
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Palantir Technologies (PLTR) is back in focus after clinching a long term US$10b U.S. Army contract and rolling out new defense and AI collaborations with GE Aerospace, Ondas, Nvidia, and key government partners. See our latest analysis for Palantir Technolo...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Palantir Technologies (PLTR) is back in focus after clinching a long term US$10b U.S. Army contract and rolling out new defense and AI collaborations with GE Aerospace, Ondas, Nvidia, and key government partners. See our latest analysis for Palantir Technologies. The recent contract wins and AI partnerships come after a sharp run earlier this year, followed by a 17.7% 3 month share price pullback and an 8.99% year to date share price decline. The 1 year total shareholder return is 77.43%, signaling strong longer term momentum despite short term volatility. If Palantir’s defense and AI deals have your attention, it can be worth scanning similar names using a focused screener for 34 AI infrastructure stocks With a US$10b Army deal, rapid AI revenue growth, and a US$11.2b backlog on one side, and high valuation concerns plus insider selling on the other, is Palantir now mispriced, or is the market already assuming that years of future growth are reflected in the current share price? Most Popular Narrative: 59.1% Overvalued According to the most followed narrative, Palantir’s fair value sits at $96 per share versus the last close of $152.77, pointing to a setup that hinges on aggressive growth and profitability assumptions. Given the valuation data provided, and drawing from broader market sentiment and historical trends, here's an analysis of Palantir Technologies Inc. including potential market risks: Valuation Analysis 1. Market Capitalization and Enterprise Value: Palantir's market capitalization increased from $13.365 billion in 2022 to $183.495 billion in 2024. The 391.13% change from 2023 to 2024 reflects a high level of market optimism. The enterprise value (EV) follows a similar trend, indicating the market's high valuation of Palantir's future potential. Read the complete narrative. The fair value in this narrative depen...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Palantir Technologies (PLTR) is back in focus after clinching a long term US$10b U.S. Army contract and rolling out new defense and AI collaborations with GE Aerospace, Ondas, Nvidia, and key government partners. See our latest analysis for Palantir Technolo...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Palantir Technologies (PLTR) is back in focus after clinching a long term US$10b U.S. Army contract and rolling out new defense and AI collaborations with GE Aerospace, Ondas, Nvidia, and key government partners. See our latest analysis for Palantir Technologies. The recent contract wins and AI partnerships come after a sharp run earlier this year, followed by a 17.7% 3 month share price pullback and an 8.99% year to date share price decline. The 1 year total shareholder return is 77.43%, signaling strong longer term momentum despite short term volatility. If Palantir’s defense and AI deals have your attention, it can be worth scanning similar names using a focused screener for 34 AI infrastructure stocks With a US$10b Army deal, rapid AI revenue growth, and a US$11.2b backlog on one side, and high valuation concerns plus insider selling on the other, is Palantir now mispriced, or is the market already assuming that years of future growth are reflected in the current share price? Most Popular Narrative: 59.1% Overvalued According to the most followed narrative, Palantir’s fair value sits at $96 per share versus the last close of $152.77, pointing to a setup that hinges on aggressive growth and profitability assumptions. Given the valuation data provided, and drawing from broader market sentiment and historical trends, here's an analysis of Palantir Technologies Inc. including potential market risks: Valuation Analysis 1. Market Capitalization and Enterprise Value: Palantir's market capitalization increased from $13.365 billion in 2022 to $183.495 billion in 2024. The 391.13% change from 2023 to 2024 reflects a high level of market optimism. The enterprise value (EV) follows a similar trend, indicating the market's high valuation of Palantir's future potential. Read the complete narrative. The fair value in this narrative depen...